How it works: Treating relapses and symptoms →

Botox, Botox Cosmetic

EU: Approved nationally (not via EMA)US: FDA approved 1991

Molecule type
Unknown
Mechanism (ChEMBL)
Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor
Targets
Synaptosomal-associated protein 25

Approvals

  • USBotox|Botox Cosmetic · Approved1991-12-09 Source

Safety communications

None recorded.

Most-reported side effects (FDA reports)

Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.

76,740 reports in total, 14,947 marked serious.

  • Drug ineffective26,602
  • Off label use11,542
  • Therapeutic response decreased4,511
  • Headache4,083
  • Product preparation error3,647
  • Injection site pain3,439
  • Eyelid ptosis3,129
  • Multiple use of single-use product2,857
  • Migraine2,351
  • Nausea2,181

Trials

Key trials

Large trials with a reported result on their main goal.

Running now

Other trials (9)

Completed small trials, dose-finding studies and trials in other diseases.

For information only, not medical advice. Talk to your neurologist before changing treatment.

Hypotheses involving this medicine

Loading hypotheses…

Loading reviews and guidelines…

Lab studies

Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.

Loading lab studies…

Assembled by software from public sources and not checked by people. Each record links to its source. Report an error